Appointed
Robert McGuire
independent director
Aerkomm Inc.
the Board appointed Mr. Robert McGuire to become an independent member of the Board effectively immediately
Executive movement radar
Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 5051–5100 of 35157
Departed
Colin Lim
independent director
Aerkomm Inc.
recently created by the resignation of two of the Company’s independent directors, Mr. Colin Lim and Mr. Raymond Choy.
Departed
Raymond Choy
independent director
Aerkomm Inc.
recently created by the resignation of two of the Company’s independent directors, Mr. Colin Lim and Mr. Raymond Choy.
Departed
Yingda Wu
Member of the Board of Directors
KUBR ·
Kuber Resources Corp
On January 20, 2025, Yingda Wu, a member of the Board of Directors of Kuber Resources Corp. (the “Company”), tendered his resign from the Company's Board of Directors, effective January 20, 2025.
Appointed
Matthew Pine
Director
TT ·
Trane Technologies plc
elected Matthew Pine, President and CEO of Xylem Inc., to serve as an independent member of the Board, effective April 1, 2025.
Appointed
Jon Paul Pérez
Director
TGLS ·
Tecnoglass Inc.
On February 4, 2025, the Board of Directors (the “Board”) of Tecnoglass Inc. (the “Company”) appointed Jon Paul “JP” Pérez to fill the vacancy on the Board created by Lorne A. Weil’s resignation previously disclosed on January 6, 2025.
Departed
Zachary Rome
Director
PaxMedica, Inc.
On January 31, 2025, Zachary Rome resigned from the Board for personal reasons, effective immediately.
Appointed
Joseph Manchin III
Director
ATH-PA ·
Athene Holding Ltd.
On February 3, 2025, former U.S. Senator Joseph Manchin III was appointed to the Board of Directors (“Board”) of Athene Holding Ltd. (the “Company”).
Appointed
Marc Carlson
Class II director
MDRR ·
Medalist Diversified, Inc.
On January 31, 2025, the Board of Directors (the “Board”) of Medalist Diversified REIT, Inc. (the “Company”) appointed Marc Carlson, as a Class II director of the Company, effective immediately.
Appointed
Charles P. Blankenship, Jr.
Director
FLR ·
FLUOR CORP
The Board elected Mr. Charles P. Blankenship, Jr., effective March 1, 2025, to fill the new position authorized by the Board.
Appointed
Dietmar Berger
Class II Director
RCUS ·
Arcus Biosciences, Inc.
On February 6, 2025, the Board appointed Dietmar Berger M.D., Ph.D., as a Class II director to fill the vacancy left by Dr. Parsey's resignation.
Departed
Merdad Parsey
Director
RCUS ·
Arcus Biosciences, Inc.
On February 6, 2025, in connection with his departure from Gilead Sciences, Inc. (“Gilead”), Merdad Parsey, M.D., Ph.D., resigned as a member of Arcus Biosciences, Inc.’s (“Arcus”) Board of Directors (the “Board”), effective upon the appointment of Gilead’s new director designee pursuant to the Amended and Restated Investor Rights Agreement dated January 29, 2024 by and between Arcus and Gilead.
Departed
Jaydriane Panis
Director
Virpax Pharmaceuticals, Inc.
Jaydriane (Jay) Panis, who resigned from the Board on February 3, 2025.
Appointed
Charn Deol
Director
Virpax Pharmaceuticals, Inc.
appointed Mr. Charn Deol as an independent director of the Company, effective immediately.
Departed
William A. Kozy
Director
COO ·
COOPER COMPANIES, INC.
On January 31, 2025, William A. Kozy informed the Board of Directors (the "Board") that he will retire as a director, effective on the date of The Cooper Companies, Inc.'s (the "Company's") next Annual Meeting of Stockholders in April 2025 (the "Annual Meeting").
Departed
Busy Burr
Director
Maverick Merger Sub 2, LLC
On January 31, 2025, Busy Burr notified the Board of Directors (the “Board”) of Mr. Cooper Group Inc. (the “Company”) that she has decided to resign from the Board effective immediately.
Appointed
Craig R. Jalbert
Director
Viracta Therapeutics, Inc.
the Board appointed Craig R. Jalbert, age 63, as the Company's Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary, and sole member of the Board.
Departed
Roger Pomerantz
Director
Viracta Therapeutics, Inc.
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Departed
Thomas E. Darcy
Director
Viracta Therapeutics, Inc.
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Departed
Mark Rothera
Director
Viracta Therapeutics, Inc.
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Departed
Ivor Royston
Director
Viracta Therapeutics, Inc.
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Departed
Flavia Borellini
Director
Viracta Therapeutics, Inc.
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Appointed
Brendan L. Hoffman
Class II Director
VNCE ·
VINCE HOLDING CORP.
In addition, the Board has elected Mr. Hoffman to serve on the Board as a Class II director, effective as of February 6, 2025.
Appointed
Rajesh Kalathur
director
AMT ·
AMERICAN TOWER CORP /MA/
On February 5, 2025, the Board of Directors (the “Board”) of American Tower Corporation (the “Company”) elected Rajesh (“Raj”) Kalathur as a director and member of its Audit Committee, effective immediately.
Appointed
Nancy Lurker
Director
COLL ·
COLLEGIUM PHARMACEUTICAL, INC
approved the expansion of the Board from eight directors to nine directors and the appointment of Nancy Lurker to serve as a director of the Board, effective as of February 4, 2025
Appointed
Chris Cleary
Class II director
OBIO ·
Orchestra BioMed Holdings, Inc.
appointed Chris Cleary to serve as a Class II director, effective immediately
Departed
Eric Rose
director
OBIO ·
Orchestra BioMed Holdings, Inc.
On February 3, 2025, Eric Rose, M.D., notified the Company of his resignation from the Board, effective immediately.
Appointed
Alexander C. Matina
Director
TPHS ·
Trinity Place Holdings Inc.
the Board will consist of five (5) members, who will initially be: (i) Jack L. Howard (Chairman), (ii) Alexander C. Matina, (iii) Joseph Martin, (iv) Jeffrey S. Wald, and (v) Joanne M. Minieri.
Appointed
Joanne M. Minieri
Director
TPHS ·
Trinity Place Holdings Inc.
the Board will consist of five (5) members, who will initially be: (i) Jack L. Howard (Chairman), (ii) Alexander C. Matina, (iii) Joseph Martin, (iv) Jeffrey S. Wald, and (v) Joanne M. Minieri.
Departed
Dan Bartok
Director
TPHS ·
Trinity Place Holdings Inc.
Each of Matthew Messinger, Keith Pattiz and Dan Bartok have tendered their resignation from the Board and as a member of any committees of the Board, which resignation will become effective immediately at the Closing Date
Appointed
Jeffrey S. Wald
Director
TPHS ·
Trinity Place Holdings Inc.
the Board will consist of five (5) members, who will initially be: (i) Jack L. Howard (Chairman), (ii) Alexander C. Matina, (iii) Joseph Martin, (iv) Jeffrey S. Wald, and (v) Joanne M. Minieri.
Departed
Matthew Messinger
Director
TPHS ·
Trinity Place Holdings Inc.
Each of Matthew Messinger, Keith Pattiz and Dan Bartok have tendered their resignation from the Board and as a member of any committees of the Board, which resignation will become effective immediately at the Closing Date
Departed
Keith Pattiz
Director
TPHS ·
Trinity Place Holdings Inc.
Each of Matthew Messinger, Keith Pattiz and Dan Bartok have tendered their resignation from the Board and as a member of any committees of the Board, which resignation will become effective immediately at the Closing Date
Appointed
Joseph Martin
Director
TPHS ·
Trinity Place Holdings Inc.
the Board will consist of five (5) members, who will initially be: (i) Jack L. Howard (Chairman), (ii) Alexander C. Matina, (iii) Joseph Martin, (iv) Jeffrey S. Wald, and (v) Joanne M. Minieri.
Appointed
Joakim Weidemanis
Member of the Board of Directors
JCI ·
Johnson Controls International plc
The Company expects that Mr. Weidemanis will be appointed as a member of the Board of Directors following his succession to the role of Chief Executive Officer.
Appointed
Daniel Hart
Director
Avid Bioservices, Inc.
Daniel Hart was appointed a director of the Company.
Departed
Esther Alegria
Director
Avid Bioservices, Inc.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed
Richard Hancock
Director
Avid Bioservices, Inc.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed
Joseph Carleone
Director
Avid Bioservices, Inc.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed
Gregory Sargen
Director
Avid Bioservices, Inc.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed
Jeanne Thoma
Director
Avid Bioservices, Inc.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed
Catherine Mackey
Director
Avid Bioservices, Inc.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed
Richard Hancock
Director
Avid Bioservices, Inc.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed
Esther Alegria
Director
Avid Bioservices, Inc.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed
Joseph Carleone
Director
Avid Bioservices, Inc.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed
Catherine Mackey
Director
Avid Bioservices, Inc.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed
Gregory Sargen
Director
Avid Bioservices, Inc.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Appointed
Daniel Hart
Director
Avid Bioservices, Inc.
Following the Effective Time, Nicholas Green remains a director of the Company and Daniel Hart was appointed a director of the Company.
Departed
Jeanne Thoma
Director
Avid Bioservices, Inc.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Appointed
M. Max Yzaguirre
Class I Director
SEI ·
Solaris Energy Infrastructure, Inc.
increased the size of the Board from nine (9) to ten (10) directors and in connection therewith appointed Mr. M. Max Yzaguirre as a Class I director
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.